The -174 G/C polymorphism of the interleukin-6 gene promoter and essential hypertension in an elderly Italian population

Journal of Human Hypertension

Volumn 16, Issue 9, 2002, Pages 637-640

  Pola, Rob ^a   Flex, A ^a   Gaetani, E ^a   Pola, P ^a   Bernabei, R ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Essential hypertension; Gene polymorphism; IL 6; Inflammatory cytokines

Indexed keywords

CYTOKINE; INTERLEUKIN 6;

AGE; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE MARKER; ENZYME ANALYSIS; ESSENTIAL HYPERTENSION; FEMALE; GENDER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; GERIATRIC PATIENT; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFLAMMATION; ITALY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN RESTRICTION; STATISTICAL SIGNIFICANCE; TISSUE INJURY;

AGED; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; INTERLEUKIN-6; ITALY; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 0036744603     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001462     Document Type: Article

References (35)

1. Taylor WR. Hypertensive vascular disease and inflammation: mechanical and humoral mechanisms. Curr Hypertens Rep 1999; 1: 96-101.
2. Intengan HD et al. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587.
3. Dzielak DJ. The immune system and hypertension. Hypertension 1992; 19: 36-44.
4. Fu ML. Do immune system changes have a role in hypertension? J Hypertens 1995; 13: 1259-1265.
5. Peeters AC et al. Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest 2001; 31: 31-36.
6. Chen CM et al. Elevation of plasma immunoglobulin A in the spontaneously hypertensive rat. Hypertension 1993; 21: 731-738.
7. Heinrich PC et al. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
8. Heinrich PC et al. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
9. Biasucci LM et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874-847.
10. Ridker PM et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.
11. Dalmon J et al. The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 1993; 13: 1183-1193.
12. Lowe GDO et al. Coagulation, fibrinolysis and cardiovascular disease. Fibrinolysis and Proteolysis 1999; 13: 91-98.
13. Woodward M et al. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999; 104: 246-257.
14. Takana M et al. Interleukin-6 as a mediator responsible for inflammation-induced increase in plasma angiotensinogen. Biochem Pharmacol 1993; 45: 201-206.
15. Soden M et al. Angiotensinogen: an acute-phase protein? Hypertension 1994; 23: 126-130.
16. Kranzhofer R et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623-1629.
17. Yudkin JS et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
18. Mohamed-Ali V et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
19. Greenwel P et al. Induction of an acute phase response in rats stimulates the expression of alpha 1(I) procollagen messenger ribonucleic acid in their livers. Possible role of interleukin-6. Lab Invest 1995; 72: 83-91.
20. Silacci P et al. Interleukin (IL)-6 and its soluble receptor induced TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. Biol Chem 1998; 273: 13625-13629.
21. Fishman D et al. The effect of novel polymorphism in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
22. Terry CF et al. Cooperative influence of genetic polymorphisms on interleukin-6 transcriptional regulation. J Biol Chem 2000; 275: 18138-18144.
23. Fernandez-Real JM et al. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000; 85: 1334-1339.
24. Rauramaa R et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2657-2662.
25. Rus HG et al. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127: 263-271.
26. Sukovich DA et al. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17βestradiol. Arterioscler Thromb Vasc Biol 1998; 18: 1498-1505.
27. Jones KG et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 2260-2265.
28. Humphries SE et al. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22: 2243-2252.
29. Nakajima T et al. Allelic variants in the interleukin-6 gene and essential hypertension in Japanese women. Genes Immun 1999; 1: 115-119.
30. Van Snick J. Interleukin-6: an overview. Ann Rev Immunol 1990; 8: 253-278.
31. Papanicolau DA et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.
32. Marian AJ. On genetics, inflammation, and abdominal aortic aneurysm. Circulation 2001; 103: 2222-2224.
33. Bowcock AM et al. The human 'interferon-beta 2/hepatocyte stimulating factor/interleukin-6′ gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics 1988; 3: 8-16.
34. Bagli M et al. Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population. Neurosci Lett 2000; 283: 109-112.
35. Yamashita J et al. Opposite regulation of Gax homeo-box expression by angiotensin II and C-type natriuretic peptide. Hypertension 1997; 29: 381-387.